The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer

YILDIZ, RAMAZAN; Benekli, Mustafa; Buyukberber, Suleyman; Kaya, Ali; Ozturk, Banu; Yaman, Emel; Berk, Veli; Coskun, UĞUR; Yamac, Deniz; Sancak, Banu; ÜNER, AYTUĞ

doi:10.1007/s00432-010-0803-1

The effect of bevacizumab on serum soluble FAS/FASL and TRAIL and its receptors (DR4 and DR5) in metastatic colorectal cancer

Atıf İçin Kopyala

YILDIZ R., Benekli M., Buyukberber S., Kaya A. O., Ozturk B., Yaman E., ...Daha Fazla

JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, cilt.136, sa.10, ss.1471-1476, 2010 (SCI-Expanded)

Yayın Türü: Makale / Tam Makale
Cilt numarası: 136 Sayı: 10
Basım Tarihi: 2010
Doi Numarası: 10.1007/s00432-010-0803-1
Dergi Adı: JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY
Derginin Tarandığı İndeksler: Science Citation Index Expanded (SCI-EXPANDED), Scopus
Sayfa Sayıları: ss.1471-1476
Gazi Üniversitesi Adresli: Evet

Özet

Bevacizumab-based chemotherapy has become the standard of care in metastatic colorectal cancer (MCRC). We aimed to measure the levels of serum soluble FAS, FASL, tumor necrosis factor-related apoptosis-inducing ligand (TRAIL), and its death receptors DR4 and DR5 in MCRC patients and to define prognostic significance of these parameters in response to bevacizumab in these patients.